JP2020502248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502248A5 JP2020502248A5 JP2019534685A JP2019534685A JP2020502248A5 JP 2020502248 A5 JP2020502248 A5 JP 2020502248A5 JP 2019534685 A JP2019534685 A JP 2019534685A JP 2019534685 A JP2019534685 A JP 2019534685A JP 2020502248 A5 JP2020502248 A5 JP 2020502248A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- preparation according
- treating
- compound
- cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000031464 Cavernous Central Nervous System Hemangioma Diseases 0.000 claims 2
- 201000008450 Intracranial aneurysm Diseases 0.000 claims 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022105969A JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437181P | 2016-12-21 | 2016-12-21 | |
| US62/437,181 | 2016-12-21 | ||
| PCT/US2017/031836 WO2018118109A1 (en) | 2016-12-21 | 2017-05-09 | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105969A Division JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502248A JP2020502248A (ja) | 2020-01-23 |
| JP2020502248A5 true JP2020502248A5 (enExample) | 2020-06-18 |
| JP7117306B2 JP7117306B2 (ja) | 2022-08-12 |
Family
ID=62627011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534685A Active JP7117306B2 (ja) | 2016-12-21 | 2017-05-09 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
| JP2022105969A Active JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105969A Active JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP3558314B1 (enExample) |
| JP (2) | JP7117306B2 (enExample) |
| DK (1) | DK3558314T3 (enExample) |
| ES (1) | ES3002432T3 (enExample) |
| FI (1) | FI3558314T3 (enExample) |
| PL (1) | PL3558314T3 (enExample) |
| PT (1) | PT3558314T (enExample) |
| WO (1) | WO2018118109A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| WO2018118109A1 (en) * | 2016-12-21 | 2018-06-28 | BioAxone BioSciences, Inc. | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
| WO2019014322A1 (en) | 2017-07-11 | 2019-01-17 | BioAxone BioSciences, Inc. | KINASE INHIBITORS FOR THE TREATMENT OF DISEASES |
| DK3877364T3 (da) * | 2018-11-06 | 2024-09-23 | Cervello Therapeutics LLC | Rock-kinasehæmmere |
| US12253482B2 (en) | 2019-11-01 | 2025-03-18 | Kirin Holdings Kabushiki Kaisha | Method for determining structure of substance in multicomponent sample |
| WO2021100852A1 (ja) * | 2019-11-21 | 2021-05-27 | キリンホールディングス株式会社 | 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法 |
| JP7213839B2 (ja) * | 2019-11-21 | 2023-01-27 | キリンホールディングス株式会社 | 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法 |
| WO2023060820A1 (zh) * | 2021-10-15 | 2023-04-20 | 合肥中科普瑞昇生物医药科技有限公司 | 胃癌原代细胞的培养基和培养方法 |
| CA3238227A1 (en) | 2021-11-11 | 2023-05-19 | The Doshisha | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040266755A1 (en) * | 2003-05-29 | 2004-12-30 | Schering Aktiengesellschaft | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine |
| EP1720874A4 (en) * | 2004-02-24 | 2010-03-03 | Bioaxone Therapeutique Inc | 4-SUBSTITUTED PIPERIDINE DERIVATIVES |
| JP4652112B2 (ja) | 2005-04-26 | 2011-03-16 | 富士フイルム株式会社 | 投射型表示装置 |
| CN101622243B (zh) | 2007-02-28 | 2013-12-04 | 旭化成制药株式会社 | 磺酰胺衍生物 |
| EP2323659A4 (en) | 2008-08-05 | 2012-03-14 | Abbott Lab | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES |
| US8957093B2 (en) | 2011-06-06 | 2015-02-17 | The Scripps Research Institute | N-biphenylmethylindole modulators of PPARG |
| BR112015021458B1 (pt) * | 2013-03-06 | 2022-06-07 | Incyte Holdings Corporation | "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases |
| WO2015165341A1 (zh) * | 2014-04-28 | 2015-11-05 | 南京明德新药研发股份有限公司 | 作为rho激酶抑制剂的异喹啉磺酰衍生物 |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| US9687483B2 (en) * | 2015-01-26 | 2017-06-27 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors |
| WO2018118109A1 (en) | 2016-12-21 | 2018-06-28 | BioAxone BioSciences, Inc. | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
-
2017
- 2017-05-09 WO PCT/US2017/031836 patent/WO2018118109A1/en not_active Ceased
- 2017-05-09 ES ES17882341T patent/ES3002432T3/es active Active
- 2017-05-09 DK DK17882341.5T patent/DK3558314T3/da active
- 2017-05-09 FI FIEP17882341.5T patent/FI3558314T3/fi active
- 2017-05-09 PL PL17882341.5T patent/PL3558314T3/pl unknown
- 2017-05-09 EP EP17882341.5A patent/EP3558314B1/en active Active
- 2017-05-09 PT PT178823415T patent/PT3558314T/pt unknown
- 2017-05-09 JP JP2019534685A patent/JP7117306B2/ja active Active
- 2017-05-09 EP EP24208222.0A patent/EP4509138A3/en active Pending
-
2022
- 2022-06-30 JP JP2022105969A patent/JP7461414B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502248A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| EP4321513A3 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| FI3558314T3 (fi) | Rho-kinaasin estäjä ba-1049 (r) ja sen aktiivisia aineenvaihduntatuotteita | |
| JP2018024670A5 (enExample) | ||
| MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
| JP2014221779A5 (enExample) | ||
| JP2017506627A5 (enExample) | ||
| JP2015513557A5 (enExample) | ||
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| WO2015171610A3 (en) | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| WO2017090039A3 (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| EP3412668A3 (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| JP2017517565A5 (enExample) | ||
| MA55917A (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
| WO2017117070A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| JP2016540015A5 (enExample) | ||
| WO2016199076A3 (en) | Polymorphic forms of afatinib free base and afatinib dimaleate | |
| TN2015000356A1 (en) | Bicyclic compounds | |
| MX2020012336A (es) | Formulacion farmaceutica. | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| EP3419981A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| JP2018145180A5 (enExample) |